JP5449774B2 - αｖβ６ペプチドリガンド及びその活用 - Google Patents

αｖβ６ペプチドリガンド及びその活用 Download PDF

Info

Publication number
JP5449774B2
JP5449774B2 JP2008534069A JP2008534069A JP5449774B2 JP 5449774 B2 JP5449774 B2 JP 5449774B2 JP 2008534069 A JP2008534069 A JP 2008534069A JP 2008534069 A JP2008534069 A JP 2008534069A JP 5449774 B2 JP5449774 B2 JP 5449774B2
Authority
JP
Japan
Prior art keywords
peptide
αvβ6
helix
a20fmdv2
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008534069A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009509562A (ja
JP2009509562A5 (https=
Inventor
マーク・ジェイ・ハワード
ダニエル・ディカラ
ジョン・エフ・マーシャル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of JP2009509562A publication Critical patent/JP2009509562A/ja
Publication of JP2009509562A5 publication Critical patent/JP2009509562A5/ja
Application granted granted Critical
Publication of JP5449774B2 publication Critical patent/JP5449774B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2008534069A 2005-10-03 2006-10-03 αｖβ６ペプチドリガンド及びその活用 Active JP5449774B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0520068A GB0520068D0 (en) 2005-10-03 2005-10-03 av peptide ligand
GB0520068.8 2005-10-03
PCT/GB2006/003673 WO2007039728A2 (en) 2005-10-03 2006-10-03 AVß6 PEPTIDE LIGANDS AND THEIR USES

Publications (3)

Publication Number Publication Date
JP2009509562A JP2009509562A (ja) 2009-03-12
JP2009509562A5 JP2009509562A5 (https=) 2009-11-12
JP5449774B2 true JP5449774B2 (ja) 2014-03-19

Family

ID=35395162

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008534069A Active JP5449774B2 (ja) 2005-10-03 2006-10-03 αｖβ６ペプチドリガンド及びその活用

Country Status (7)

Country Link
US (3) US8383593B2 (https=)
EP (1) EP1957522B1 (https=)
JP (1) JP5449774B2 (https=)
CA (2) CA2624618C (https=)
ES (1) ES2638439T3 (https=)
GB (1) GB0520068D0 (https=)
WO (1) WO2007039728A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0520068D0 (en) 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
TW200815474A (en) 2006-08-03 2008-04-01 Astrazeneca Ab Antibodies alphaVbeta6 and uses thereof
GB0718843D0 (en) 2007-09-26 2007-11-07 Cancer Rec Tech Ltd Materials and methods relating to modifying the binding of antibodies
MX342270B (es) * 2010-02-18 2016-09-21 The Regents Of The Univ Of California * ANTICUERPO NEUTRALIZANTE DE LA INTEGRINA AVß8.
WO2013025261A2 (en) * 2011-04-06 2013-02-21 Georgia Tech Research Corporation Fluorogenic peptide probes and assays
WO2013078250A2 (en) * 2011-11-22 2013-05-30 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides that bind alpha-v-beta-6 integrin
US9403877B2 (en) 2012-01-24 2016-08-02 Inter-K Pty Limited Peptide agents for cancer therapy
US9282120B2 (en) * 2013-02-01 2016-03-08 Vidder, Inc. Securing communication over a network using client integrity verification
GB201311031D0 (en) * 2013-06-20 2013-08-07 Queen Mary & Westfield College Method
JP6789823B2 (ja) * 2014-04-15 2020-11-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 両末端ｐｅｇ化インテグリン結合性ペプチドおよびその使用方法
GB201513540D0 (en) 2015-07-31 2015-09-16 King S College London Therapeutic agents
EP3468984A4 (en) * 2016-06-13 2020-03-11 The Regents of the University of California ALPHA (V) BETA (6) BINDING PEPTIDES AND METHODS OF USE THEREOF
BR112018076184A2 (pt) * 2016-06-16 2019-03-26 The University Of Liverpool composição sólida, composição farmacêutica ou veterinária na forma injetável, formulação intramuscularmente injetável, formulação subcutaneamente injetável, dispersão aquosa, dispersão oleosa, processos para preparar uma composição sólida, uma dispersão aquosa e uma dispersão oleosa, métodos para tratar e/ou prevenir uma infecção parasítica ou fúngica e para prevenir malária, e, kit para preparação de uma formulação líquida estéril de nanopartículas de atovaquona para injeção.
ES3023938T3 (en) 2016-09-29 2025-06-03 Univ California Neutralizing antibodies to the alpha v beta 8 integrin complex for immunotherapy
SI3535397T1 (sl) * 2016-11-01 2022-04-29 Arrowhead Pharmaceuticals, Inc. Ligandi alfa-V beta-6 integrina in njihove uporabe
GB201706472D0 (en) * 2017-04-24 2017-06-07 Cancer Res Tech Ltd Tumour-targeting peptide variants
JP7445594B2 (ja) 2017-11-01 2024-03-07 アローヘッド ファーマシューティカルズ インコーポレイテッド インテグリンリガンドおよびその使用
GB201802539D0 (en) * 2018-02-16 2018-04-04 Univ College Cardiff Consultants Ltd Modified adenoviruses
EP3846858A4 (en) * 2018-09-07 2022-10-19 The Regents of the University of California Alpha(v)beta(6) integrin-binding peptides and methods of use thereof
AU2020370362A1 (en) * 2019-10-25 2022-06-02 Children's Medical Center Corporation Computational design of alpha(v) beta (6) integrin binding proteins
WO2021094608A1 (en) * 2019-11-15 2021-05-20 Ospedale San Raffaele S.R.L. Chromogranin a-derived peptides and uses thereof
US12486502B2 (en) 2021-04-08 2025-12-02 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use
WO2022221144A1 (en) * 2021-04-12 2022-10-20 University Of Washington Engineered peptides for αvβ6 integrin binding and related methods of use and synthesis
CN115010949B (zh) * 2022-07-12 2024-02-13 华熙生物科技股份有限公司 促渗物、护肤品组合物以及化妆品

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8301928D0 (en) 1983-01-24 1983-02-23 Nicholson B H Process for producing polypeptides
JPS60103596A (ja) * 1983-11-11 1985-06-07 Toshiba Corp サンプル・ホ−ルド回路
AUPM411994A0 (en) * 1994-02-25 1994-03-24 Deakin Research Limited Epitopes
EP1140989A1 (de) 1998-12-19 2001-10-10 MERCK PATENT GmbH Inhibitoren des integrins alpha(v) beta(6)
DE19929410A1 (de) * 1999-06-26 2000-12-28 Merck Patent Gmbh Inhibitoren des Integrins avß6
DE19933173A1 (de) * 1999-07-15 2001-01-18 Merck Patent Gmbh Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶
JP2003534558A (ja) * 2000-05-26 2003-11-18 グラクソ グループ リミテッド ＬＡＰ（潜在型結合ペプチド）とインテグリンαｖβ３との間の相互作用のモジュレーターを同定する方法及びその医学的使用
US20030031648A1 (en) * 2000-11-28 2003-02-13 Virogene Ltd. Vectors for expressing heterologous peptides at the amino-terminus of potyvirus coat protein, methods for use thereof, plants infected with same and methods of vaccination using same
GB0520068D0 (en) 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand

Also Published As

Publication number Publication date
EP1957522A2 (en) 2008-08-20
ES2638439T3 (es) 2017-10-20
WO2007039728A3 (en) 2007-09-20
US20150125392A1 (en) 2015-05-07
US20090123370A1 (en) 2009-05-14
CA2624618A1 (en) 2007-04-12
US20130149248A1 (en) 2013-06-13
WO2007039728A2 (en) 2007-04-12
CA2854550C (en) 2020-04-14
JP2009509562A (ja) 2009-03-12
CA2854550A1 (en) 2007-04-12
GB0520068D0 (en) 2005-11-09
EP1957522B1 (en) 2017-07-12
US9650416B2 (en) 2017-05-16
US8383593B2 (en) 2013-02-26
CA2624618C (en) 2016-03-29
US8927501B2 (en) 2015-01-06

Similar Documents

Publication Publication Date Title
JP5449774B2 (ja) αｖβ６ペプチドリガンド及びその活用
Jin et al. The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination
US11390646B2 (en) Structure-based peptide inhibitors of α-synuclein aggregation
CA2650113C (en) Compositions for treatment of cancer
Patra et al. Chemically modified peptides targeting the PDZ domain of GIPC as a therapeutic approach for cancer
US10400010B2 (en) Structure-based peptide inhibitors of P53 aggregation as a new approach to cancer therapeutics
CN101384618A (zh) 癌中capcna蛋白-蛋白相互作用的肽基抑制
Enyedi et al. Development of cyclic NGR peptides with thioether linkage: structure and dynamics determining deamidation and bioactivity
Su et al. A high hydrophobic moment arginine‐rich peptide screened by a machine learning algorithm enhanced ADC antitumor activity
Liao et al. A Dual-Specificity d-Peptide Antagonist of MDM2 and MDMX for Antitumor Immunotherapy
Goda et al. Intracellular protein delivery activity of peptides derived from insulin-like growth factor binding proteins 3 and 5
JP2005510460A (ja) 分子
US12098175B2 (en) Peptide inhibitors targeting the CXCL12/HMGB1 interaction and uses thereof
US20140005119A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVITY OF P110a MUTANT PROTEINS
CN109311962A (zh) Bcl-2 l10/ip3受体相互作用的抑制剂
Class et al. Patent application title: STRUCTURE-BASED PEPTIDE INHIBITORS OF P53 AGGREGATION AS A NEW APPROACH TO CANCER THERAPEUTICS Inventors: David S. Eisenberg (Los Angeles, CA, US) Alice Soragni (Los Angeles, CA, US) Lin Jiang (Los Angeles, CA, US) Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Herrera Evaluation of NMR structural studies on a family of membrane active channel forming peptides
Lazic Receptor associated protein (RAP): Its structural organization and interaction with LRP

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120514

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131225

R150 Certificate of patent or registration of utility model

Ref document number: 5449774

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250